Research has found that resveratrol, a compound present naturally in grape skin, can protect against the cellular damage to blood vessels caused by high production of glucose in diabetes.

Sirtris Pharmaceuticals, Inc., has been issued a patent for a new class of drugs called SIRT1 Activators (resveratrol), which lower glucose and improve insulin sensitivity In preclinical models of type 2 diabetes.

Individuals who have one or two parents with hypertension appear to have a significantly increased risk of developing elevated blood pressure throughout their adult lives.

Weight-loss and major lifestyle changes may be more effective than intensive insulin therapy for overweight patients with poorly controlled, insulin-resistant type 2 diabetes, according to a diabetes researcher at UT Southwestern Medical Center.

According to a study in the November/December 2007 issue of General Dentistry, the AGD’s clinical, peer-reviewed journal, diabetic patients especially need to communicate special needs to their dentists. This is due to harmful interactions that could occur because of the materials and medications used at dental appointments.

People who have diabetes encounter a faster loss of lung capacity than those who do not have diabetes, a finding that may have implications for the potential use of future inhaled insulins’. It was concluded that medical professionals need to pay more attention to lung function.

A study has found evidence that pregnant women with periodontal (gum) disease have an increased risk of developing gestational diabetes than pregnant women with healthy gums.

This week’s new tool is all about dental health and diabetes. Brian L. Mealey DDS, MS Department of Periodontics University of Texas San Antonio has written an opinion in Endocrinology, Diabetes & Obesity on the relationship of Diabetes mellitus and inflammatory periodontal diseases. Click here to read what he has …

Data from the ADVANCE Study, involving 11,140 high-risk patients with type 2 diabetes, provides no evidence of an increased risk of death among those patients receiving aggressive treatment to lower blood glucose.

The FDA has approved insulin aspart (rDNA origin) injection (NovoLog) for continuous subcutaneous insulin infusion (CSII) by external insulin pump in pediatric patients aged 4 to 18 years. It is the first and only insulin analog approved for this use